Search results
Results From The WOW.Com Content Network
Pfizer reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations and its stock remained flat after market open.Pfizer reported $63.6 billion in ...
PFE earnings call for the period ending December 31, 2024. ... The impact of catastrophic coverage is expected to exceed the potential volume benefit from the reduction of the patient out-of ...
PFE earnings call for the period ending September 30, ... All in, these items are expected to have a favorable impact on full year 2024 adjusted diluted earnings per share of approximately $0.30.
(Reuters) -Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, boosted by cost cutting efforts and stronger-than-expected sales ...
The company, raised its full-year guidance by $1.5 billion and beat Wall Street estimates in its third quarter earnings Tuesday. Pfizer now expects between $61 billion and $64 billion in revenue ...
A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. ... Analysts expect earnings of 61 cents per share in the third ...
PFE earnings call for the period ending June 30, 2024. ... Vyndaqel, Eliquis and Xtandi. As expected, dampening our growth in the quarter were Xeljanz and Ibrance.
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.